Results from the phase 3 SELECT-CHOICE study comparing treatment with upadacitinib to abatacept, a selective T cell costimulation modulator, in adults with moderate to severe active rheumatoid arthritis.
An investigational type 1 interferon receptor inhibitor was associated with significant reduction in disease activity in patients with systemic lupus erythematosus.
In a study of lenabasum treatment in systemic sclerosis, researchers evaluated variability of immunosuppressive therapy by geographic region; includes Q&A with study lead author, Dr Christopher Denton.